SG11201809534UA - Methods of treating autoimmune disease using allogeneic t cells - Google Patents
Methods of treating autoimmune disease using allogeneic t cellsInfo
- Publication number
- SG11201809534UA SG11201809534UA SG11201809534UA SG11201809534UA SG11201809534UA SG 11201809534U A SG11201809534U A SG 11201809534UA SG 11201809534U A SG11201809534U A SG 11201809534UA SG 11201809534U A SG11201809534U A SG 11201809534UA SG 11201809534U A SG11201809534U A SG 11201809534UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- herston
- pct
- allogeneic
- methods
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 230000000735 allogeneic effect Effects 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 11 11111111111E1111111111 0010101111111111111111111111011111011110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/203368 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: A61K 35/17 (2015.01) A61P 37/00 (2006.01) A61K 39/245 (2006.01) Cl 2N 5/0783 (2010.01) (21) International Application Number: PCT/IB2017/000805 (22) International Filing Date: 25 May 2017 (25.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,360 25 May 2016 (25.05.2016) US 62/359,326 07 July 2016 (07.07.2016) US 62/487,814 20 April 2017 (20.04.2017) US (71) Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 300 Herston Rd., Herston, QLD 4006 (AU). (72) Inventor: KHANNA, Rajiv; 59 Aberleigh Road, Herston, QLD 4006 (AU). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) under Rule 4.17: Declarations of inventorship (Rule 4.17(iv)) — ,— I Published: ..! — with international search report (Art. 21(3)) — GC before the expiration of the time limit for amending the V::+ claims and to be republished in the event of receipt of M amendments (Rule 48.2(h)) M 0 N _ N (54) Title: METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENEIC T CELLS 1-1 0 (57) : Provided herein are compositions comprising allogeneic cytotoxic T cells expressing a T cell receptor that specifically N binds to an Epstein-Barr virus (EBV) peptide presented on a class I MHC and methods of treating autoimmune diseases with this 0 composition.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341360P | 2016-05-25 | 2016-05-25 | |
| US201662359326P | 2016-07-07 | 2016-07-07 | |
| US201762487814P | 2017-04-20 | 2017-04-20 | |
| PCT/IB2017/000805 WO2017203368A1 (en) | 2016-05-25 | 2017-05-25 | Methods of treating autoimmune disease using allogeneic t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809534UA true SG11201809534UA (en) | 2018-12-28 |
Family
ID=60411139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809534UA SG11201809534UA (en) | 2016-05-25 | 2017-05-25 | Methods of treating autoimmune disease using allogeneic t cells |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210220402A1 (en) |
| EP (1) | EP3463399A4 (en) |
| JP (2) | JP7136701B2 (en) |
| KR (2) | KR20230113817A (en) |
| CN (1) | CN109475578A (en) |
| AU (2) | AU2017271134A1 (en) |
| BR (1) | BR112018073136A2 (en) |
| CA (1) | CA3024277A1 (en) |
| CL (1) | CL2018003284A1 (en) |
| IL (1) | IL262989A (en) |
| MX (1) | MX2018013959A (en) |
| PH (1) | PH12018502402A1 (en) |
| SG (1) | SG11201809534UA (en) |
| WO (1) | WO2017203368A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| ES2748652T3 (en) | 2012-02-09 | 2020-03-17 | Baylor College Medicine | Pep mixes to generate multiviral CTLs with broad specificity |
| CN108449994B (en) | 2015-09-18 | 2021-10-01 | 贝勒医学院 | Identification of immunogenic antigens from pathogens and correlation with clinical efficacy |
| SG10202007893TA (en) | 2016-05-25 | 2020-10-29 | Council Queensland Inst Medical Res | Methods of immunotherapy |
| TW201840327A (en) * | 2017-01-20 | 2018-11-16 | 昆士蘭醫學研究所理事會 | Methods of treating multiple sclerosis using autologous t cells |
| EP3737394A4 (en) * | 2018-01-08 | 2021-11-10 | Atara Biotherapeutics, Inc. | Systems and methods for distributing cell therapies |
| EP3807423A4 (en) * | 2018-06-13 | 2022-04-27 | The Council Of The Queensland Institute Of Medical Research | Viral detection assay |
| SG11202101468XA (en) | 2018-09-10 | 2021-04-29 | Atara Biotherapeutics Inc | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto |
| WO2020162696A1 (en) * | 2019-02-08 | 2020-08-13 | 주식회사 굳티셀 | Method for t cell activation for cancer treatment |
| MX2022001322A (en) * | 2019-07-29 | 2022-05-24 | Baylor College Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO784197A0 (en) * | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US20030147865A1 (en) * | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20090324630A1 (en) * | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| AU2012258603A1 (en) * | 2011-05-26 | 2014-01-16 | Geneius Biotechnology, Inc. | Modulated immunodominance therapy |
| US10351824B2 (en) * | 2011-12-12 | 2019-07-16 | Cell Medica Limited | Process of expanding T cells |
| CN104491857B (en) * | 2014-12-24 | 2018-08-31 | 深圳市中美康士生物科技有限公司 | A kind of antigen composition for immunization therapy EBV relevant diseases, biological agent and preparation method thereof |
-
2017
- 2017-05-25 US US16/303,680 patent/US20210220402A1/en not_active Abandoned
- 2017-05-25 KR KR1020237023943A patent/KR20230113817A/en not_active Application Discontinuation
- 2017-05-25 WO PCT/IB2017/000805 patent/WO2017203368A1/en unknown
- 2017-05-25 SG SG11201809534UA patent/SG11201809534UA/en unknown
- 2017-05-25 CN CN201780045908.6A patent/CN109475578A/en active Pending
- 2017-05-25 JP JP2018561493A patent/JP7136701B2/en active Active
- 2017-05-25 BR BR112018073136-6A patent/BR112018073136A2/en unknown
- 2017-05-25 CA CA3024277A patent/CA3024277A1/en active Pending
- 2017-05-25 EP EP17802272.9A patent/EP3463399A4/en active Pending
- 2017-05-25 AU AU2017271134A patent/AU2017271134A1/en not_active Abandoned
- 2017-05-25 MX MX2018013959A patent/MX2018013959A/en unknown
- 2017-05-25 KR KR1020187037500A patent/KR20190030661A/en not_active IP Right Cessation
-
2018
- 2018-11-13 IL IL262989A patent/IL262989A/en unknown
- 2018-11-14 PH PH12018502402A patent/PH12018502402A1/en unknown
- 2018-11-19 CL CL2018003284A patent/CL2018003284A1/en unknown
-
2022
- 2022-04-22 US US17/727,107 patent/US20220409662A1/en not_active Abandoned
- 2022-09-01 JP JP2022138871A patent/JP7454617B2/en active Active
-
2024
- 2024-07-12 AU AU2024204831A patent/AU2024204831A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516751A (en) | 2019-06-20 |
| JP2022174151A (en) | 2022-11-22 |
| MX2018013959A (en) | 2019-08-22 |
| WO2017203368A1 (en) | 2017-11-30 |
| IL262989A (en) | 2018-12-31 |
| US20220409662A1 (en) | 2022-12-29 |
| US20210220402A1 (en) | 2021-07-22 |
| JP7136701B2 (en) | 2022-09-13 |
| EP3463399A1 (en) | 2019-04-10 |
| CA3024277A1 (en) | 2017-11-30 |
| BR112018073136A2 (en) | 2019-03-12 |
| KR20230113817A (en) | 2023-08-01 |
| PH12018502402A1 (en) | 2019-04-08 |
| KR20190030661A (en) | 2019-03-22 |
| EP3463399A4 (en) | 2020-03-18 |
| JP7454617B2 (en) | 2024-03-22 |
| CL2018003284A1 (en) | 2019-06-14 |
| RU2018145500A3 (en) | 2020-10-15 |
| CN109475578A (en) | 2019-03-15 |
| AU2017271134A1 (en) | 2019-01-03 |
| AU2024204831A1 (en) | 2024-08-01 |
| RU2018145500A (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201903427UA (en) | Deodorizing agent comprising zinc neodecanoate | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof |